The abstract is read at the publisher; the summary is JClub's.
Dual CD19- and BCMA-targeted CAR T-cell therapy enabled kidney transplantation in two highly sensitized end-stage kidney disease candidates with panel-reactive antibody score ≥99.9%.
- Why it matters: HLA sensitization is a major barrier to kidney transplantation, and prior antibody-elimination approaches have often failed to sustain reductions in anti-HLA antibodies in the most highly sensitized patients.
- What they did: In a multicenter phase 1 safety run-in cohort (NCT06056102), the study used combined CD19- and BCMA-targeted CAR T cells to eliminate cellular sources of preformed anti-HLA antibodies before transplant.
- The result: Kidney transplantation was performed in two highly sensitized candidates after desensitization, supporting the safety feasibility of this dual CAR T-cell approach for this subgroup.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.